Coldstream Capital Management Inc. Cuts Stock Position in DexCom, Inc. $DXCM

Coldstream Capital Management Inc. cut its position in DexCom, Inc. (NASDAQ:DXCM) by 22.2% in the second quarter, HoldingsChannel.com reports. The firm owned 8,564 shares of the medical device company’s stock after selling 2,446 shares during the period. Coldstream Capital Management Inc.’s holdings in DexCom were worth $748,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Nuveen LLC purchased a new position in shares of DexCom in the 1st quarter worth approximately $554,893,000. Massachusetts Financial Services Co. MA boosted its stake in DexCom by 106.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after acquiring an additional 1,868,241 shares in the last quarter. DSM Capital Partners LLC grew its holdings in DexCom by 252.1% in the second quarter. DSM Capital Partners LLC now owns 1,435,296 shares of the medical device company’s stock worth $125,287,000 after purchasing an additional 1,027,633 shares during the last quarter. Finally, Jennison Associates LLC increased its position in shares of DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after purchasing an additional 994,300 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other DexCom news, Director Kyle Malady sold 667 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach purchased 18,200 shares of the business’s stock in a transaction on Monday, November 10th. The shares were bought at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at $18,256,602.88. This trade represents a 5.81% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders sold 9,999 shares of company stock worth $619,391. Company insiders own 0.32% of the company’s stock.

DexCom Trading Up 1.4%

Shares of NASDAQ:DXCM opened at $62.53 on Thursday. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The stock has a market cap of $24.39 billion, a price-to-earnings ratio of 43.42, a PEG ratio of 1.43 and a beta of 1.40. The business has a 50-day moving average price of $64.66 and a 200-day moving average price of $76.13.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the prior year, the firm earned $0.45 earnings per share. DexCom’s revenue for the quarter was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DXCM. Weiss Ratings reissued a “sell (d+)” rating on shares of DexCom in a research report on Monday. The Goldman Sachs Group lowered their price target on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a report on Wednesday, October 1st. Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Truist Financial reaffirmed a “buy” rating and issued a $82.00 price objective (down from $94.00) on shares of DexCom in a research report on Monday, November 3rd. Finally, Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $86.73.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.